Key result
CPAP shows no impact on serum adiponectin levels in patients with OSA.
Why the study?
Previous studies assessing the effect of CPAP on adiponectin levels in patients with OSA yielded conflicting results.
Does continuous positive airway pressure (CPAP) therapy increase serum adiponectin levels in patients with obstructive sleep apnea?
Meta-Analysis (n=240)
Does continuous positive airway pressure (CPAP) therapy increase serum adiponectin levels in patients with obstructive sleep apnea?
Standardized Mean Difference: 0.059 (95% CI -0.25–0.368)
p-value: p=0.710
CPAP therapy does not significantly alter serum adiponectin levels or body weight in patients with obstructive sleep apnea.
CPAP leaves adiponectin unchanged in OSA; leaves open any metabolic benefit via other pathways and requires larger RCTs.
OBJECTIVE: Obstructive sleep apnea (OSA) has been suggested to be associated with low levels of adiponectin. Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA; however, previous studies assessing the effect of CPAP on adiponectin in patients with OSA yielded conflicting results. The present meta-analysis was performed to determine whether CPAP therapy could increase adiponectin levels. METHODS: Two reviewers independently searched PubMed, Cochrane library, Embase and Web of Science before February 2015. Information on characteristics of subjects, study design and pre- and post-CPAP treatment of serum adiponectin was extracted for analysis. Standardized mean difference (SMD) was used to analyze the summary estimates for CPAP therapy. RESULTS: Eleven studies involving 240 patients were included in this meta-analysis, including ten observational studies and one randomized controlled study. The meta-analysis showed that there was no change of adiponectin levels before and after CPAP treatment in OSA patients (SMD = 0.059, 95% confidence interval (CI) = -0.250 to 0.368, z = 0.37, p = 0.710). Subgroup analyses indicated that the results were not affected by age, baseline body mass index, severity of OSA, CPAP therapy duration, sample size and racial differences. CONCLUSIONS: This meta-analysis suggested that CPAP therapy has no impact on adiponectin in OSA patients, without significant changes in body weight. Further large-scale, well-designed long-term interventional investigations are needed to clarify this issue.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2015) conducted a meta-analysis in Obstructive sleep apnea (n=240). Continuous positive airway pressure (CPAP) vs. Pre-CPAP treatment (baseline) was evaluated on Change in serum adiponectin levels before and after CPAP treatment (SMD 0.059, 95% CI -0.250 to 0.368, p=0.710). Continuous positive airway pressure therapy had no significant impact on serum adiponectin levels in patients with obstructive sleep apnea (SMD 0.059, p=0.710).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: